Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items: 2018-2025

Historic Non-cash Items for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Jun 2025 value amounting to $81.3 million.

  • Crinetics Pharmaceuticals' Non-cash Items fell 71.88% to $81.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.3 million, marking a year-over-year decrease of 71.88%. This contributed to the annual value of $337.7 million for FY2024, which is 60.88% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Non-cash Items of $81.3 million as of Q2 2025, which was down 40.43% from $136.4 million recorded in Q1 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-cash Items ranged from a high of $337.7 million in Q4 2024 and a low of $2,172 during Q1 2021.
  • Its 3-year average for Non-cash Items is $123.7 million, with a median of $108.8 million in 2025.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Non-cash Items soared by 1,996,631.12% in 2022, and later slumped by 95.75% in 2024.
  • Crinetics Pharmaceuticals' Non-cash Items (Quarterly) stood at $80.9 million in 2021, then plummeted by 71.39% to $23.1 million in 2022, then soared by 806.67% to $209.9 million in 2023, then skyrocketed by 60.88% to $337.7 million in 2024, then crashed by 71.88% to $81.3 million in 2025.
  • Its Non-cash Items stands at $81.3 million for Q2 2025, versus $136.4 million for Q1 2025 and $337.7 million for Q4 2024.